High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy (2014)

Peer-Reviewed Study · Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q · February 5, 2014

Ma Y et al., 2014-02-05: The 2014 Science Translational Medicine study the book cites: millimolar ascorbate acted as a pro-oxidant in ovarian cancer cells, and IV ascorbate plus carboplatin/paclitaxel inhibited ovarian tumours in mice and lowered chemotherapy toxicity in a small patient cohort.

The combination of parenteral ascorbate with the conventional chemotherapeutic agents carboplatin and paclitaxel synergistically inhibited ovarian cancer in mouse models and reduced chemotherapy-associated toxicity in patients with ovarian cancer.

Abstract (Sci Transl Med 6(222):222ra18)

Ma Y et al., 2014-02-05: The 2014 Science Translational Medicine study the book cites: millimolar ascorbate acted as a pro-oxidant in ovarian cancer cells, and IV ascorbate plus carboplatin/paclitaxel inhibited ovarian tumours in mice and lowered chemotherapy toxicity in a small patient cohort. The claim's 'up to 50%' tumour-growth figure is NOT in the abstract, and the full text is paywalled with no PMC copy (Europe PMC: isOpenAccess=N, inPMC=N), so it could not be verified against the paper. Secondary summary of the same paper (The ASCO Post, 2014-02-10) reports the triple combination 'reduced tumor weight by 94% compared to controls', i.e. a larger effect than 50% in mice; that figure is the news summary's, not checked against the paper. Human component was a pilot phase I/IIa (27 patients), not a randomised trial. Funding and author disclosures not captured (no accessible full text); authors are University of Kansas Medical Center and NIH (Levine) researchers; no commercial ascorbate maker named. Comparator in mice: carboplatin/paclitaxel alone and untreated controls. Study type: controlled study.